Nectin Therapeutics Licenses Novel ADC-Related Antibodies to Immunome

Nectin Therapeutics announced a global, exclusive license agreement with Immunome Inc. for a panel of antibodies targeting an undisclosed target

The agreement allows Nectin to focus on its anti-PVR program (NTX1088) and advance its novel ADCs into clinical development

Immunome received exclusive, worldwide rights to the monoclonal antibodies and will handle their research, development, manufacturing, and commercialization

Nectin will receive an upfront payment and be eligible for milestones and royalties from Immunome

Both companies expressed confidence in the partnership, emphasizing the potential of pairing high-quality antibodies with innovative linker-payload technology for next-generation ADC therapies